BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 23403007)

  • 1. Enhancing cytokine-induced killer cell therapy of multiple myeloma.
    Liu C; Suksanpaisan L; Chen YW; Russell SJ; Peng KW
    Exp Hematol; 2013 Jun; 41(6):508-17. PubMed ID: 23403007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of NKG2D in cytokine-induced killer cells against multiple myeloma cells.
    Lu X; Zhu A; Cai X; Jia Z; Han W; Ma L; Zhou M; Qian K; Cen L; Chen B
    Cancer Biol Ther; 2012 Jun; 13(8):623-9. PubMed ID: 22555808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells.
    Su X; Zhang L; Jin L; Ye J; Guan Z; Chen R
    J Clin Immunol; 2010 Sep; 30(5):766-74. PubMed ID: 20549316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition.
    Wei F; Rong XX; Xie RY; Jia LT; Wang HY; Qin YJ; Chen L; Shen HF; Lin XL; Yang J; Yang S; Hao WC; Chen Y; Xiao SJ; Zhou HR; Lin TY; Chen YS; Sun Y; Yao KT; Xiao D
    Oncotarget; 2015 Oct; 6(33):35023-39. PubMed ID: 26418951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma.
    Nwangwu CA; Weiher H; Schmidt-Wolf IGH
    Hematol Oncol; 2017 Dec; 35(4):719-725. PubMed ID: 27430430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.
    Liu C; Russell SJ; Peng KW
    Mol Ther; 2010 Jun; 18(6):1155-64. PubMed ID: 20234340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
    Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
    Front Immunol; 2021; 12():731767. PubMed ID: 34691037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.
    Pievani A; Borleri G; Pende D; Moretta L; Rambaldi A; Golay J; Introna M
    Blood; 2011 Sep; 118(12):3301-10. PubMed ID: 21821703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic effect of cytokine-induced killer cell with valproate inhibits growth of hepatocellular carcinoma cell in a mouse model.
    Lee DH; Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho E; Lee JH; Yu SJ; Kim YJ; Yoon JH
    Cancer Biol Ther; 2017 Jan; 18(1):67-75. PubMed ID: 28055304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models.
    Shi S; Wang R; Chen Y; Song H; Chen L; Huang G
    PLoS One; 2013; 8(6):e65757. PubMed ID: 23799045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cord blood CD4
    Liu A; Wang Q; Yang X; Shen S; Xu Y
    Front Biosci (Landmark Ed); 2019 Jun; 24(7):1259-1270. PubMed ID: 31136978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapeutic effects of cytokine-induced killer cells combined with CCL21/IL15 armed oncolytic adenovirus in TERT-positive tumor cells.
    Ye JF; Lin YQ; Yu XH; Liu MY; Li Y
    Int Immunopharmacol; 2016 Sep; 38():460-7. PubMed ID: 27380620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.
    Iudicone P; Fioravanti D; Cicchetti E; Zizzari IG; Pandolfi A; Scocchera R; Fazzina R; Pierelli L
    Hum Immunol; 2016 Dec; 77(12):1239-1247. PubMed ID: 27615504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
    Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
    Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.
    Dingli D; Peng KW; Harvey ME; Greipp PR; O'Connor MK; Cattaneo R; Morris JC; Russell SJ
    Blood; 2004 Mar; 103(5):1641-6. PubMed ID: 14604966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts.
    Poh SL; Linn YC
    Cancer Immunol Immunother; 2016 May; 65(5):525-36. PubMed ID: 26961084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
    Garg TK; Szmania SM; Khan JA; Hoering A; Malbrough PA; Moreno-Bost A; Greenway AD; Lingo JD; Li X; Yaccoby S; Suva LJ; Storrie B; Tricot G; Campana D; Shaughnessy JD; Nair BP; Bellamy WT; Epstein J; Barlogie B; van Rhee F
    Haematologica; 2012 Sep; 97(9):1348-56. PubMed ID: 22419581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy with cytokine-induced killer cells and oncolytic adenovirus expressing IL-12 induce enhanced antitumor activity in liver tumor model.
    Yang Z; Zhang Q; Xu K; Shan J; Shen J; Liu L; Xu Y; Xia F; Bie P; Zhang X; Cui Y; Bian XW; Qian C
    PLoS One; 2012; 7(9):e44802. PubMed ID: 23028626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.